Lupin is currently trading at Rs. 735.20, up by 0.55 points or 0.07% from its previous closing of Rs. 734.65 on the BSE.
The scrip opened at Rs. 734.00 and has touched a high and low of Rs. 741.00 and Rs. 731.10 respectively. So far 36910 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 723.55 on 15-May-2018.
Last one week high and low of the scrip stood at Rs. 757.15 and Rs. 726.00 respectively. The current market cap of the company is Rs. 33371.41 crore.
The promoters holding in the company stood at 46.98%, while Institutions and Non-Institutions held 38.84% and 14.18% respectively.
Lupin has received the ‘European Good Manufacturing Practice’ (EU GMP) certificate for its Mammalian Facility in Pune where Etanercept Biosimilar is intended to be manufactured. This GMP certification further confirms that the company has a robust manufacturing facility that ensures consistent and controlled production as per EU quality standards.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1817.60 |
Dr. Reddys Lab | 1351.25 |
Cipla | 1475.90 |
Lupin | 2168.30 |
Zydus Lifesciences | 964.40 |
View more.. |